AIOctant is building Octomind to help scientists run drug-discovery programs
An Octant team member describes Octomind as more like “Claude Code for drug hunters” for now. The goal is a fully agentic drug hunter, but its decision-making layer remains the furthest from finished.
TLDR
An Octant team member says the company is building Octomind around a program knowledge base, an execution engine and a decision layer, testing the approach in its Gates Foundation-funded HPV work. The aim is to connect scientific context with experiments and use results to choose what to do next. In an early test, Octomind ranked 20 compounds for follow-up. But the author says the team has not yet shown that its choices improve the program or beat what its drug hunters would have done. Scientists would initially set goals, correct context, review analyses and approve actions.
Octant is building Octomind to help scientists run drug-discovery programs
An Octant team member describes Octomind as more like “Claude Code for drug hunters” for now. The goal is a fully agentic drug hunter, but its decision-making layer remains the furthest from finished.
TLDR
An Octant team member says the company is building Octomind around a program knowledge base, an execution engine and a decision layer, testing the approach in its Gates Foundation-funded HPV work. The aim is to connect scientific context with experiments and use results to choose what to do next. In an early test, Octomind ranked 20 compounds for follow-up. But the author says the team has not yet shown that its choices improve the program or beat what its drug hunters would have done. Scientists would initially set goals, correct context, review analyses and approve actions.